GlobeNewswire·Nov 13, 2025, 4:05 PM ET

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

JBIO

Jade Biosciences presented favorable preclinical safety data for JADE101 & a translational analysis of APRIL-mediated biomarker responses at the American Society of Nephrology Kidney Week 2025.
The company initiated a Phase 1 healthy volunteer study for JADE101, with interim biomarker-rich data expected in the first half of 2026 to define dosing for future patient trials.
Jade unveiled JADE201, a half-life extended, afucosylated anti-BAFF receptor monoclonal antibody, with a first-in-human rheumatoid arthritis trial expected to begin in the first half of 2026.
The company completed a $135 million private placement, extending its cash runway into the first half of 2028.
JADE101 demonstrated well-tolerated safety in non-human primates with no off-target binding or broad immune suppression, supporting its potential as a selective therapy for IgA nephropathy.
Translational assessments linked APRIL inhibition biomarkers in healthy volunteers to anticipated therapeutic outcomes in IgA nephropathy patients.
JADE201 showed high-affinity BAFF-R binding, sustained B-cell depletion, & an approximately two-fold extended half-life compared to ianalumab in non-human primate studies.
Third quarter 2025 Research & Development expenses totaled $22.0 million, driven by increased personnel costs & early clinical activity.
Third quarter 2025 General & Administrative expenses totaled $5.4 million, primarily due to higher personnel costs for infrastructure expansion.
The company reported a net loss of $25.2 million for the quarter ended September 30, 2025.
As of September 30, 2025, cash, cash equivalents, & investments were $198.9 million, rising to approximately $325.6 million on a pro-forma basis after the private placement.
Post-financing, Jade had 67,394,380 million shares of common stock & common stock equivalents issued & outstanding.